数据
资源
版本对比
免费注册
预约演示
免费注册
Ortho Dermatologics
to Present New Data at the 2022 Innovations in Dermatology Conference
2022-11-01
·
BioSpace
Nine Poster Presentations Include New Analyses of
SILIQ
® and
JUBLIA
® LAVAL, QC / ACCESSWIRE / November 1, 2022 / -
Bausch Health Companies Inc.
(NYSE:BHC)(TSX:BHC) ("Bausch Health") and its dermatology business,
Ortho Dermatologics
, today announced the presentation of nine posters during the Innovations in Dermatology Conference, which takes place Nov. 3-5, 2022, in Las Vegas, Nev. The presentations will feature new data around
JUBLIA
® (
efinaconazole
) Topical Solution, 10%, and
SILIQ
® (
brodalumab
) Injection, 210 mg/1.5 mL. There will also be six encore presentations, including analyses of DUOBRII® (
halobetasol propionate
and
tazarotene
) Lotion, 0.01%/0.045%,
ARAZLO
® (
tazarotene
) Lotion, 0.045%, and the investigational medicine
IDP-126
Gel-a combination retinoid, antibacterial and antibiotic topical. "Continued research around our products is a top priority for us at
Ortho Dermatologics
to ensure our portfolio meets the needs of patients," said Richard Lajoie, vice president and general manager,
Ortho Dermatologics
. "At this year's Innovations in Dermatology Conference, we look forward to the opportunity to directly engage with dermatologists and share new data on
JUBLIA
®, which received the APMA Seal of Approval in December 2021, as well as our biologic
psoriasis
medication,
SILIQ
®. " The complete list of Ortho Dermatologics' poster presentations is as follows:
JUBLIA
® (
efinaconazole
) Topical Solution, 10% "Combination Therapy With
Efinaconazole
for the Treatment of
Toenail Onychomycosis
." Lipner et al. "Therapeutic Recommendations for the Treatment of Toenail
Onychomycosis
in the US." Lipner et al. SILIQ® (
brodalumab
) Injection, 210 mg/1.5 mL "
Brodalumab
Provides Rapid Onset of Therapeutic Response for Patients With Moderate-to-Severe
Psoriasis
." Armstrong et al. "Long-term Skin Clearance Achieved in Moderate-to-Severe
Psoriasis
Through
Interleukin-17 Receptor A
Blockade." Lain et al. "
Brodalumab
: 4-Year US Pharmacovigilance Report." Lebwohl et al.
ARAZLO
® (
tazarotene
) Lotion, 0.045% "
Tazarotene
0.045% Lotion for
Truncal Acne
: Efficacy, Tolerability, and Spreadability." Kircik et al.
DUOBRII
® (
halobetasol propionate
and
tazarotene
) Lotion, 0.01%/0.045% "Fixed-Combination
Halobetasol Propionate
and
Tazarotene
Lotion for the Treatment of
Plaque Psoriasis
in Patients With Affected Body Surface Area of 3% to 5% and Poor Quality of Life." Stein Gold et al. "Importance of Topical Vehicle Design for the Treatment of
Psoriasis
: A Review of Fixed-Combination
Halobetasol Propionate
and
Tazarotene
Lotion." Stein Gold et al.
IDP-126
Gel (Investigational Drug) "Efficacy and Safety of a Fixed-Dose
Clindamycin
1.2%,
Benzoyl Peroxide
3.1%, and
Adapalene
0.15% Gel for Moderate-to-Severe
Acne
: Randomized Phase 2 and Phase 3 Studies of the First Triple-Combination Drug." Stein Gold et al. Important Safety Information for
JUBLIA
® (
efinaconazole
) Topical Solution, 10% INDICATION
JUBLIA
(
efinaconazole
) Topical Solution, 10% is a prescription medicine used to treat
fungal infections
of the toenails. IMPORTANT SAFETY INFORMATION
JUBLIA
is for use on nails and surrounding skin only. Do not use
JUBLIA
in your mouth, eyes, or vagina. Use it exactly as instructed by your doctor. The safety and efficacy of
JUBLIA
have not been established in children under six years old. Before you use
JUBLIA
, tell your doctor about all your medical conditions, including if you are or plan to become pregnant, are breastfeeding, or plan to breastfeed, because it is not known whether
JUBLIA
can harm an unborn fetus or nursing infant. Tell your doctor about all medications you are taking, and whether you have any other
nail infections
.
JUBLIA
is flammable. Avoid heat and flame while applying
JUBLIA
to your toenail.
JUBLIA
may cause irritation at the treated site. The most common side effects include: ingrown toenail,
redness
,
itching
,
swelling
, burning or stinging,
blisters
, and
pain
. Tell your doctor about any side effects that bother you or do not go away. To report SUSPECTED ADVERSE REACTIONS, contact
Ortho Dermatologics
at 1-800-321-4576 or the FDA at 1-800-FDA-1088 or visit . Please click here for full Prescribing Information, including Patient Information. Visit to learn more. Important Safety Information for
SILIQ
® (
brodalumab
) Injection, 210 mg/1.5 mL What is SILIQ?
SILIQ
(
brodalumab
) injection is indicated for the treatment of moderate-to-severe
plaque psoriasis
in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. What is the most important information I should know about SILIQ? Suicidal thoughts or behavior: Some patients taking
SILIQ
have had suicidal thoughts or ended their own lives. This risk is higher if you have a history of suicidal thoughts or
depression
. It is not known if
SILIQ
causes these thoughts or actions. Get medical help right away if you or a family member notices that you have any of the following symptoms: new or worsening
depression
,
anxiety
, or
mood problems
; thoughts of suicide, dying, or hurting yourself; attempt to commit suicide, or acting on dangerous impulses; other unusual changes in your behavior or mood. Your healthcare provider will give you a SILIQ patient/wallet card about symptoms that need medical attention right away. Carry the card with you during treatment with
SILIQ
and show it to all of your healthcare providers. This is not all the Important Safety Information you need to know about
SILIQ
. Please click here for full Prescribing Information for
SILIQ
, including Boxed Warning about
suicidal ideation
and behavior, and Medication Guide. Important Safety Information for
ARAZLO
® (
tazarotene
) Lotion, 0.045% What is
ARAZLO
?
ARAZLO
® (
tazarotene
) Lotion, 0.045% is a prescription medicine used on the skin (topical) to treat people 9 years of age and older with
acne
, which can include blackheads, whiteheads, and other pimples. It is not known if
ARAZLO
is safe and effective in children under 9 years of age. Important Safety Information
ARAZLO
is for use on skin only. Do not use
ARAZLO
in your eyes, mouth, the corners of your nose, or vagina. What is the most important information I should know about
ARAZLO
?
ARAZLO
may cause
birth defects
if used during pregnancy. You must not be pregnant when you start using
ARAZLO
or become pregnant during treatment. Use effective birth control during treatment. Stop using
ARAZLO
and tell your healthcare provider right away if you become pregnant during treatment. Before using
ARAZLO
, tell your healthcare provider about all your medical conditions, including if you: have
eczema
or any other skin problems. are breastfeeding or plan to breastfeed. If you use
ARAZLO
while breastfeeding, use it for the shortest time needed. Do not apply
ARAZLO
directly to the nipple and surrounding area to avoid exposing your child to the medicine. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines can make your skin more sensitive to sunlight; ask your healthcare provider for a list of medicines if you are not sure. Especially tell your healthcare provider about other products you use on your skin (such as
benzoyl peroxide
), including moisturizers, creams, lotions, or products that can dry out your skin. What should I avoid while using
ARAZLO
? You should avoid sunlamps, tanning beds, and ultraviolet light during treatment with
ARAZLO
. Minimize exposure to sunlight; you could get severe
sunburn
. If you have to be in the sunlight or are sensitive to sunlight, use a sunscreen with an SPF (sun protection factor) of 15 or more and wear protective clothing and a wide-brimmed hat to cover the treated areas. Avoid using
ARAZLO
on skin with
eczema
or sunburned skin because it may cause severe irritation.
ARAZLO
may cause side effects, including:
Skin irritation
.
ARAZLO
may cause irritation including
skin dryness
,
pain
,
redness
, excessive flaking or peeling. If you develop these symptoms, your healthcare provider may tell you to use a moisturizer, adjust the dosing, or completely stop treatment with
ARAZLO
. These are not all the possible side effects of
ARAZLO
. Call your doctor for medical advice about side effects. You may report side effects to
Bausch Health US, LLC
at 1-800-321-4576 or FDA at 1-800-FDA-1088 or . Click here for full Prescribing Information, including Patient Information. Important Safety Information for
DUOBRII
® (
halobetasol propionate
and
tazarotene
) Lotion, 0.01%/0.045%
DUOBRII
(
halobetasol propionate
and
tazarotene
) Lotion, 0.01%/0.045%, is a prescription medicine used on the skin (topical) to treat adults with
plaque psoriasis
. It is not known if
DUOBRII
Lotion is safe and effective in children.
DUOBRII
Lotion is for use on the skin only; do not use it in your mouth, eyes, or vagina.
DUOBRII Lotion
may cause
birth defects
if used during pregnancy. Stop using DUOBRII Lotion and tell your healthcare provider right away if you become pregnant while using DUOBRII Lotion.
DUOBRII
may cause side effects, including: If too much
DUOBRII
passes through your skin it can cause adrenal glands to stop working
Cushing's syndrome
, a condition from too much exposure to the hormone cortisol High blood sugar (hyperglycemia) The most common side effects of
DUOBRII
Lotion include
redness
,
itching
,
swelling
, burning, stinging,
application site pain
, inflamed hair follicles (
folliculitis
), thinning of the skin (
atrophy
), peeling and
rash
. To report SUSPECTED ADVERSE REACTIONS, contact Ortho Dermatologics at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit . This is not all of the Important Safety Information you need to know about
DUOBRII
; please click here for full Prescribing Information, including Patient Information. About
Ortho Dermatologics
Ortho Dermatologics
is one of the largest prescription and aesthetic dermatology businesses dedicated to helping patients in the treatment of a range of therapeutic areas, including
psoriasis
,
onychomycosis
,
actinic keratosis
,
acne
,
atopic dermatitis
and other
dermatoses
. The Ortho Dermatologics portfolio also includes several leading medical device systems for aesthetic applications, such as skin tightening and resurfacing, laser hair removal and preventative therapeutic skin care treatments. More information can be found at . About
Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our healthcare products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership interest in
Bausch + Lomb Corporation
. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit and connect with us on Twitter and LinkedIn. Forward-looking Statements This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving
COVID-19 pandemic
, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof.
Bausch Health
undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. Contact:
Bausch
Health Investor Contact: Christina Cheng ir@bauschhealth.com Bausch Health Media Contact: Kevin Wiggins corporate.communications@bauschhealth.com JUBLIA, SILIQ, ARAZLO, and DUOBRII are trademarks of
Ortho Dermatologics
' affiliated entities.
Ortho Dermatologics
is a trademark of
Ortho Dermatologics
' affiliated entities. © 2022
Ortho Dermatologics
' affiliated entities. ORD.0140.USA.22 SOURCE:
Bausch Health Companies Inc
View source version on accesswire.com:
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Ortho Dermatologics
Bausch & Lomb, Inc.
Bausch Health US LLC
[+1]
适应症
湿疹
疼痛
先天性畸形
[+24]
靶点
IL-17RA
药物
布罗利尤单抗
艾氟康唑
丙酸乌倍他索
[+6]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务